Paul Mattels

Stock Analyst at Stifel

(n/a)

# 4,986

Out of 5,182 analysts

5

Total ratings

n/a

Success rate

-22.93%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Paul Mattels

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	DNLI Denali Therapeutics	Maintains: Buy	$34 → $41	$19.29	+112.55%	4	Mar 26, 2026
	ALEC Alector	Initiates: Buy	$44	$2.40	+1,733.33%	1	Feb 19, 2020

Denali Therapeutics

Mar 26, 2026

Maintains: Buy

Price Target: $34 → $41

Current: $19.29

Upside: +112.55%

Alector

Feb 19, 2020

Initiates: Buy

Price Target: $44

Current: $2.40

Upside: +1,733.33%